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rejection group, whose tubuli had only minimal staining forNature and mediators of renal lesions in kidney transplant
RANTES mRNA on a few occasions.patients given cyclosporine for more than one year.
Conclusion. Long-term CsA administration to kidney allo-Background. Cyclosporine (CsA) has improved patients and
graft recipients leads to tubulointerstitial injury independentlyorgan-graft survival rates, but its chronic nephrotoxicity is still
of its vascular effect. The possible contribution to the develop-an issue. Although prolonged vasoconstriction could contribute
ment of interstitial fibrosis of inflammatory and growth factorsto chronic CsA tubulointerstitial changes by producing chronic
released by tubular cells in which CsA accumulates is proposed.ischemia, this relationship has been difficult to demonstrate
thus far, and cellular origin and mediators of these structural
alterations remain ill-defined.
Methods. As a part of a clinical trial in kidney transplant
Cyclosporine (CsA) has improved patient and organ-recipients on triple immunosuppressive therapy (CsA, azathio-
graft survival rates. Indeed, in the past two decades,prine and steroid), which includes renal biopsy as “per proto-
col,” 22 patients enrolled between 12 and 24 months post- short-term success rates of kidney, heart, liver, and kid-
transplantation underwent renal hemodynamic evaluation by ney/pancreas allografts have reached unprecedented lev-
measuring glomerular filtration rate and renal plasma flow by els, largely attributable to CsA immunosuppression [1–3].the plasma clearance of unlabeled iohexol and the renal clear-
However, nephrotoxicity of CsA continues to be an issueance of para-aminohippuric acid, respectively. In parallel, the
[4–6], with a wide spectrum of effects ranging from markedCsA pharmacokinetic profile was also determined. A week
later, a protocol biopsy of kidney graft was performed. Light and rapidly reversible renal hypoperfusion, which fol-
microscopy examination and localization of endothelin-1, lows each dosing, to a chronic form of renal injury that
RANTES, monocyte chemoattractant protein-1 gene expres- manifests after one or more years of treatment [7–9],sion by in situ hybridization in the graft specimens were evalu-
and may have a progressive course in certain instancesated and related to the pattern of histologic lesions.
[10]. Although acute renal hypoperfusion induced byResults. Ten out of 22 kidney transplant recipients who un-
derwent the protocol biopsy had CsA nephrotoxicity, eight CsA is no longer a problem, chronic CsA nephrotoxicity
had chronic rejection, and four had no lesions at histological remains a major challenge for transplant physicians. Le-
examination. The total daily exposure to CsA was higher in
sions of chronic CsA nephropathy consist of vascularpatients with CsA nephrotoxicity than in those with chronic
and tubulointerstitial changes, including degenerativerejection or no lesions at biopsy. Renal function was preserved
in the CsA toxicity group as compared with the chronic rejec- hyaline alterations extending from preglomerular areas
tion group, despite some degree of renal hypoperfusion. Tubu- proximally up the afferent arteriole [11], with progressive
lar atrophy and striped interstitial fibrosis were found in all narrowing and eventual occlusion of the lumen. Tubulo-
patients with light microscopical evidence of CsA nephrotoxic-
interstitial changes are narrow stripes of atrophy andity, whereas glomerular and arteriolar lesions were less fre-
fibrosis, mostly corresponding to areas of cortex withquent. Intense staining for endothelin-1, RANTES, and mono-
cyte chemoattractant protein-1 mRNAs selectively localized afferent arteriolar lesions [12], but can be diffuse. The
at tubular epithelial cells was found in biopsies taken from precise cause of CsA renal toxicity is not known. It may
patients with CsA nephrotoxicity, but not in the chronic graft be that sustained glomerular afferent arteriolar vasocon-
striction eventually promotes structural alteration and
eventual occlusion of preglomerular vessels [5, 10, 13].Key words: nephrotoxicity, vasoconstriction, renal transplantation,
interstitial fibrosis, endothelin-1, RANTES, MCP-1 This determines an ischemic damage of downstream glo-
meruli and interstitium that culminates in glomerular ob-Received for publication June 26, 1998
solescence and interstitial fibrosis. Although prolongedand in revised form September 2, 1998
Accepted for publication September 3, 1998 vasoconstriction could contribute to chronic CsA ne-
phropathy by producing chronic ischemia, this relation- 1999 by the International Society of Nephrology
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Table 1. Characteristic at enrollment of kidney transplant recipients given preoperatively and throughout the four-day post-
given cyclosporine for more than one year
operative period by intravenous infusion at a daily dose
Age years 44 6 12 (24–66) of 4 mg/kg/day. Thereafter, CsA was administered orally
Gender M/F 16/6 at full dose and was then progressively tapered to mainte-Time of CsA treatment before
nance dose within the next three months. The steroidbiopsy months 17 6 4 (13–24)
Dose of CsA at biopsy mg/kg/day 3.42 6 0.66 (2.21–4.96) (methylprednisolone) was given preoperatively at the
Serum creatinine mg/dl 1.3 6 0.3 (0.8–2.0) dose of 500 mg intravenously, then orally (prednisolone)Proteinuria g/24 hr 0.39 6 0.48 (0.80–1.62)
in a single morning dose tapered to 16 mg until the end
Values are mean 6 sd, range. CsA is cyclosporine A.
of the third month, and then progressively to 8 mg/day.
Azathioprine was given at the dose of 1 to 1.5 mg/kg/
day for the entire period. At the time of this study,
enrolled patients had normal renal function or mild toship has been difficult to demonstrate so far [14]. Attention
has been focused in the past on enhanced vasoconstric- moderate renal insufficiency. The study protocol was
described in detail to the patients before admission, andtors [such as thromboxane A2, endothelin (ET) and an-
giotensin II] [7, 15], reduced nitric oxide production [16], informed consent to perform the study and renal biopsy
was obtained in each instance. The trial was approvedor activation of renal sympathetic nerves [17] as media-
tors of renal hemodynamic changes induced by CsA, but by the appropriate Institutional Review Committee.
there is no evidence that any of these actually mediated
Study protocolstructural changes, specifically tubulointerstitial injury,
which, by the way, is seen in only CsA-treated animals Patients were asked to collect urine for measurement
of 24-hour protein excretion, starting the day beforesubjected to salt depletion [18, 19]. It appears more likely
that tubulointerstitial fibrosis associated with CsA treat- renal function evaluation. Then all patients underwent
renal hemodynamic evaluation by measuring glomerularment is a clearly separate entity that develops indepen-
dently of the vasoactive effect of the drug. filtration rate (GFR) and renal plasma flow (RPF) by
the plasma clearance of unlabeled iohexol [20] and theWe therefore designed a study in humans aimed at
evaluating the relationship between afferent arteriolar renal clearance of para-aminohippuric acid (PAH) [21],
respectively. In parallel, the CsA pharmacokinetic pro-arteriolopathy and tubulointerstitial fibrosis induced by
CsA, and to get more insights on the factor(s) mediating file was also determined.
On the morning of the study, blood was drawn fortubulointerstitial injury and possible mechanisms associ-
ated with this lesion. estimation of serum creatinine concentration and hema-
tocrit values. Renal clearance of PAH was performedThis study is a part of a clinical trial in kidney trans-
plant recipients on triple immunosuppressive therapy, under a steady state of diuresis induced by oral water
loading and subsequent water intake adjusted to main-which includes renal biopsy as “per protocol” (see Meth-
ods), and is directed towards establishing whether chang- tain urine flow relatively constant throughout the study.
A priming dose, followed by a constant infusion of 20%ing immunosuppressive therapy on the basis of histologic
findings obtained 12- to 24-months posttransplant pro- PAH, was administered. The sustained dose of PAH was
started to maintain constant plasma concentration ofvides any advantage in preventing graft function deterio-
ration as compared with patients who do not undergo 0.015 mg/ml. After a 60-minute equilibration period,
CsA was given orally, and then six carefully timed urinerenal biopsy and continue their conventional triple anti-
rejection regimen. collections (two hr each) were made. Urine was collected
by spontaneous voiding, and blood samples were drawn
at the beginning and at the end of each clearance period.
METHODS
To measure GFR, 5 ml of iohexol solution (Omni-
Patient characteristics and treatment paque 300; Nycomed, Milan, Italy) were slowly injected
into the antecubital vein just before CsA administration.Twenty-two consecutive patients (6 female, 16 male)
with end-stage renal disease who underwent kidney Plasma clearance of this x-ray agent was determined by
collecting blood samples from the contralateral arm attransplantation at the Ospedali Riuniti di Bergamo were
considered for this study (Table 1). They were outpa- 120, 180, 240, 300, 450, and 600 minutes. These time
schedules were chosen based on analysis of our previoustients regularly followed at the Unit of Nephrology of
the Department of Immunology and Clinics of Organ data showing that GFR values obtained by using these
sampling points best correlated with renal inulin clear-Transplantation and were enrolled between 12 and 24
months post-transplantation. All patients received a first ance [20].
Moreover, before CsA administration, at 30 and 60cadaveric transplant and were on maintenance immuno-
suppression with triple therapy, which included CsA minutes after CsA administration, and at hourly intervals
thereafter for 12 hours, blood samples were collected(Sandimmune), prednisone, and azathioprine. CsA was
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from a peripheral vein for measurement of CsA levels flammation were documented alone or in association
with arteriosclerotic lesions or glomerulopathy [22, 24].in the blood.
A week after the renal hemodynamic evaluation, pa- No lesions. This condition was defined when normal
pattern or borderline tubulointerstitial changes were ob-tients were again admitted to the Unit of Nephrology to
perform biopsy of the kidney allograft. In all cases, the served.
renal biopsy was done not because of renal dysfunction,
Preparation of digoxigenin-labeled, RANTES, andbut as part of the research protocol to assess the possible
monocyte chemoattractant protein-1 riboprobespresence of chronic CsA injury and thus to modify the
dosage schedule accordingly. Endothelin-1 antisense and sense probes were pre-
pared and labeled by in vitro transcription using digoxi-
Renal protocol biopsy genin-labeled uridine triphosphate as previously de-
scribed [25].Kidney graft tissue was processed for light microscopy
by fixation in Dubosq-Brazil fluid and was embedded in A 310 bp human RANTES (regulated upon activation,
normal T cell expressed and secreted) and a 340 bpparaffin. Specimens were stained with Masson’s tri-
chrome, hematoxylin and eosin, and periodic acid Schiff human monocyte chemoattractant protein-1 (MCP-1)
were subcloned into the Bam HI/Sal I and the Bam HI/reagent. Focal and segmental glomerular sclerotic lesions
were defined as an increase of mesangial matrix sub- Hind III sites, respectively, at the pBlue script II SK
vector between T3 and T7 promoters. Labeling ofstance associated with capillary wall collapse. Glomeru-
lar damage, tubular changes (atrophy, casts, and dila- RANTES and MCP-1 probes was performed as for ET-1
probes.tion), interstitial changes (fibrosis and inflammation),
and vascular lesions were graded from 0 to 31 (0 5 no
Nonisotopic in situ hybridizationchanges, 11 5 changes in less than 25% of the sample,
21 5 changes affecting 25% to 50% of the sample, and Dubosq-Brazil fixed, paraffin embedded renal tissue
was cut at 4 mm, sequentially heat fixed (658C, 30 min-31 5 more than 50% changes affecting the sample). All
renal biopsies were examined by a pathologist unaware utes), and deparaffinized. Sections were then incubated
with 5 mmol/liter levamisole for 30 minutes at roomof the clinical and laboratory data.
By light microscopy the patterns were categorized into temperature, briefly washed in phosphate-buffered sa-
line and water, and immersed in 0.2 n HCl [23]. AfterCsA nephropathy, chronic rejection, and no lesions.
CsA nephropathy. This condition was defined ac- permeabilization with proteinase K (40 mg/ml; Sigma,
St. Louis, MO, USA), slides were postfixed in 1.5% para-cording to the following changes: (a) tubular (isometric
vacuolization, inclusion bodies corresponding to giant formaldehyde/1.5% glutaraldehyde for one minute, de-
hydrated through a graded ethanol series, and air dried.mitochondria, microcalcification, and irregular foci of
tubular atrophy); (b) interstitial (striped or patchy fibro- Sections were then overlaid with a hybridization mixture
consisting of 0.5 ng/ml of various digoxigenin-labeledsis); (c) vascular—early lesions (vacuolization and clear
cell transformation of smooth muscle cells) and vascu- RNA probes, 2 3 SSC, 10% dextran sulfate, 1 3 Den-
hardt’s solution, and 0.1 mol/liter sodium phosphate cov-lar—late lesions (circular nodular hyaline deposits in
the afferent arteriolar wall, narrowing or occlusion of ered with sealed coverslips and incubated overnight in
a moist chamber at 458C for ET-1, 558C for RANTES,vascular lumen); and (d) glomerular (sclerosis or ische-
mic collapse, juxtaglomerular apparatus hyperplasia). and 508C for MCP-1. After hybridization, slides were
washed in 0.2 3 SSC, were treated with a blocking solu-CsA nephropathy was diagnosed when striped tubular
atrophy and interstitial fibrosis were found alone or in tion (50 mg/ml skimmed dried milk, 150 mmol/liter NaCl
in 100 mmol/liter Tris-HCl, pH 7.8) at room temperatureassociation with any of the morphologic lesions de-
scribed above [22, 23]. for 25 minutes, and were finally incubated for 45 minutes
at 378C with an antidigoxigenin antibody conjugated withChronic rejection. This condition was defined ac-
cording to the following changes: (a) tubular (diffuse alkaline phosphatase (Boehringer Mannheim, Mannheim,
Germany) diluted 1:1000. Color development was per-tubular atrophy, wrinkling and thickening of tubular
basement membrane, and simplification of the epithelial formed with freshly prepared substrate solution (nitro blue
tetrazolium salt and X-phosphate-5-bromo-4-chloro-3-cells); (b) interstitial (fibrosis and mononuclear cell in-
flammation); (c) vascular (arteriosclerosis with intimal indolyl phosphate 0.4 mol/liter in 0.1 mol/liter Tris-HCl,
0.1 mol/liter NaCl, 50 mmol/liter MgCl2, pH 9.5). Slidesproliferation and thickening of vessel wall of interlobular
and arcuate arteries, elastic lamina fragmentation); and were then mounted in 60% glycerol and examined by
light microscopy. Negative controls included hybridiza-(d) glomerular (wrinkled, thickened, and collapsed capil-
lary wall and mesangial expansion, sclerosis). tion step using the sense probe and omission of either the
antisense RNA probe or the antidigoxigenin antibody.Chronic rejection was diagnosed when diffuse tubular
atrophy, diffuse interstitial fibrosis, and interstitial in- To allow a semiquantitative evaluation of ET-1,
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RANTES, or MCP-1 mRNAs, the staining intensity was (Table 2). In all patients, diffuse tubular atrophy and
graded as 0 (not detectable), 1 (minimal), 2 (moderate), interstitial fibrosis were present and scored mild to se-
and 3 (strong). vere. Tubular atrophy was indicated by the thickened,
wrinkled tubular basement membranes and was associ-
Analytical procedures ated with extensive interstitial fibrosis. In the fibrotic
Plasma concentrations of iohexol were determined by interstitium, a sparse mononuclear cell infiltrate was
high-performance liquid chromatography (HPLC) as de- present in almost all patients. Glomerular lesions were
scribed previously [20]. The plasma profiles were ana- found in two patients and were characterized by focal
lyzed by a one-compartment open model system, and and segmental sclerosis in addition to wrinkling and
the calculated clearance of iohexol (as an index of GFR) thickening or collapse of capillary walls. In six patients,
was corrected according to the Brochner-Mortensen for- mild to moderate vascular alterations were documented.
mula [26]. Plasma and urine concentrations of PAH were The vessel walls, particularly of the interlobular and ar-
measured by the colorimetric method of Smith et al cuate arteries, were markedly thickened. Intimal hyper-
[27], and renal clearance was calculated according to the plasia, similar to that found in classic arteriosclerosis,
standard formula. was shown in these vessels.
Blood CsA concentration was determined by HPLC, No lesions. Four patients had a normal kidney graft
as previously described [28]. Results were expressed as at histological examination (Table 2). In three of them,
ng per ml. The blood concentration-time profile of CsA very minor tubular atrophy and interstitial fibrosis were
was recorded for all patients together with trough level observed. Interstitial inflammation was also documented
(blood concentration before the next administration). in one case. No other histological alterations, including
The area under the blood concentration curve from the glomerular and vascular lesions, were found in any of
time equals zero to the last sampling point [12 hr; area these four patients.
under the curve (AUC) from 0 to .12] was calculated
by the trapezoidal rule. Characteristics of CsA pharmacokinetics
Table 3 shows CsA pharmacokinetic parameters, in-Statistical analysis
cluding trough concentration and AUC, in the three
Data are expressed as mean 6 sd and range as speci- groups of patients. Mean trough CsA level was 24% and
fied. Results were analyzed using one-way analysis of 20% higher in patients with CsA nephrotoxicity than in
variance, and specific comparisons were performed by those with chronic rejection or no lesions at renal biopsy,
two-tailed Student’s t-test for unpaired data using the
respectively. Similarly, the total daily exposure to CsA,
Bonferroni correction. Statistical analysis was performed
measured as AUC, was elevated in patients with CsAusing the software package StatView (Abacous Concepts
nephrotoxicity (12% and 23%) as compared with pa-Inc., Berkeley, CA, USA).
tients with chronic rejection or no lesions at biopsy. De-
spite numerically higher trough CsA and AUC, values in
RESULTS patients with CsA nephrotoxicity were not significantly
different as compared with values in the two other groups.Incidence and features of histologic lesions
CsA nephropathy. Ten out of 22 patients had evidence Renal function
of CsA-induced nephrotoxicity at histological examina-
As shown in Table 3, serum creatinine level was nor-tion, as defined in Methods (Table 2). In all of these
mal in all but two patients with CsA nephrotoxicity,patients, irregular foci or stripes of tubular atrophy ac-
whereas it was elevated in seven out of eight patientscompanied by fibrosis were the predominant findings.
with chronic rejection.Areas of atrophic tubules embedded in a fibrotic intersti-
In patients with CsA nephrotoxicity, the mean GFRtium were adjacent to areas exhibiting normal tubules.
was 44% higher than in those with chronic rejection andSome tubular cells showed fine vacuolization of the cyto-
was comparable to GFR values in patients with no renalplasm. In five patients, a very mild interstitial inflamma-
lesions at histological examination (Table 3). This wouldtion was seen. Glomerular lesions, as focal-segmental
suggest that these patients were studied at an early stagesclerosis and ischemic collapse, were documented in four
of CsA toxicity. On the other hand, the mean renalpatients. Minimal to mild arteriolopathy was seen in
plasma flow (RPF) value was similar in patients withtwo patients. This was characterized by vacuolization of
CsA nephrotoxicity and in those with chronic rejection.smooth muscle cells and necrosis of individual endothe-
In both instances, RPF was numerically but not signifi-lial and smooth muscle cells associated with nodular pro-
cantly lower than in patients with no lesions at renaltein deposits in place of degenerated smooth muscle cells.
biopsy.Chronic rejection. At light microscopy of the graft
biopsy, eight patients had a diagnosis of chronic rejection Two patients in the CsA nephrotoxicity group and one
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Table 2. Individual kidney graft histopathology scores by conventional light microscopy analysis
Scores
Glomerulosclerosis Tubular atrophy Interstitial fibrosis Interstitial inflammation Vascular lesions
CsA nephrotoxicity
O.L. 1 2.5 2.5 1 1
M.M. 0 1 1 0.5 0
S.G. 1 1 1 1 0
J.B. 0 1 1 0 0
M.G. 1 1.5 1.5 0 0
M.A. 0 1 1 1 0
C.M. 0 2 2 0.5 1
C.G. 0 1 1 0 0
T.E. 1 1 1 0 0
P.G. 0 1 1 0 nv
Mean 0.4 1.3 1.3a 0.4b 0.2b
Range (0–1) (1–2.5) (1–2.5) (0–1) (0–1)
Chronic graft rejection
P.M. 1 1 1 2 1
P.A. 0 2.5 2.5 1 2
G.S. 0 1.5 1.5 1 1
P.G. 0 1 1 2.5 1.5
Z.G. 0 1 1 1 nv
T.D. 1 2 2 2 1
F.G. 0 0.5 0.5 0.5 0
A.B. 0 0.5 0.5 0.5 2
Mean 0.3 1.3 1.3 1.3c 1.2c
Range (0–1) (0.5–2.5) (0.5–2.5) (0.5–2.5) (0–2)
No lesions
L.R. 0 1 0.5 0 0
B.C. 0 0.5 0.5 0.5 0
G.S. 0 0 0 0 0
M.M. 0 0.5 0.5 0 0
Mean 0.0 0.5 0.4 0.1 0.0
Range (0–0) (0–0.5) (0–1) (0–0.5) (0–0)
Abbreviation: n.v. is no vessels in the specimen.
a P , 0.05 vs. no lesions
b P , 0.05 vs. chronic graft rejection
c P , 0.05 vs. no lesions
Table 3. Cyclosporine A (CsA) pharmacokinetic parameters, renal function and proteinuria in the three groups of patients identified
according to kidney graft biopsy examination
CsA nephrotoxicity Chronic graft rejection No lesions
Cmin ng/ml 115 6 49 (68–221) 93 6 41 (55–184) 96 6 26 (57–115)
AUC ng/ml 3 h 3301 6 909 (2328–5331) 2948 6 1529 (1466–6280) 2681 6 899 (1662–3641)
SCr mg/dl 1.2 6 0.2 (0.8–1.8) 1.5 6 0.4 (1.0–2.0) 1.1 6 0.3 (0.8–1.4)
GFR ml/min/1.73 m2 74.85 6 22.47 (38.75–103.01) 51.89 6 16.24 (24.31–68.55) 77.71 6 22.45 (49.50–100.73)
RPF ml/min/1.73 m2 323 6 91 (137–444) 295 6 76 (187–382) 329 6 47 (359–460)
Proteinuria g/24 hr 0.45 6 0.57 (1.57–0.08) 0.43 6 0.50 (1.62–0.11) 0.18 6 0.06 (0.13–0.26)
Abbreviations are: Cmin, CsA blood trough level; AUC, CsA area under the blood concentration–time curve; SCr, serum creatinine concentration; GFR, glomerular
filtration rate; RFP, renal plasma flow.
in the chronic rejection group had proteinuria (defined as which were virtually negative for the ET-1 mRNA signal
(Fig. 1). A high-intensity signal for ET-1 mRNA wasmore than 0.5 g/24 hr protein excretion; Table 3).
mainly observed in the epithelial cells of those tubules
In situ hybridization for ET-1, RANTES, and MCP-1 located in areas of interstitial fibrosis. At variance, no
mRNAs of protocol biopsies staining for ET-1 mRNA was documented in tubuli and
glomeruli of patients with chronic rejection. Very minorTable 4 summarizes the intensity scores of in situ hy-
bridization staining for ET-1, RANTES, and MCP-1 ET-1 mRNA staining intensity was seen in some patients
with no renal lesions at light microscopy. In order tomRNAs in the three groups of patients. In patients with
CsA nephrotoxicity, intense staining for ET-1 mRNA evaluate the frequency of positive in situ hybridization
in the different groups, biopsies showing a staining inten-was found in tubular epithelial cells but not in glomeruli,
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Table 4. Individual scores of tubular and glomerular staining for ET-1, RANTES, and MCP-1 mRNAs by in situ hybridization
in the three groups of patients
ET-1 mRNA RANTES mRNA MCP-1 mRNA
Score Score Score
Tubuli Glomeruli Tubuli Glomeruli Tubuli Glomeruli
CsA nephrotoxicity
O.L. 3 0 3 0 1 0
M.M. 2.5 0 0 0 1.5 0
S.G. 0 0 0 0 1 0
J.B. 0 0 0 0 0 0
M.G. 2 0 0.5 0 1.5 0
M.A. 1.5 0 1 0 0.5 0
C.M. 0.5 0 3 2 2 0
C.G. nd nd 3 1 1.5 1
T.E. 2 0 2 0 1 0
P.G. 0.5 0 2 0 0 0
Mean 1.3a 0 1.5 0.3 1.0a 0.1
Range (0–3) (0–0) (0–3) (0–2) (0–2) (0–1)
Chronic graft rejection
P.M. 0 0 1.5 0 0 0
P.A. 0.5 0 1 0 0 0
G.S. 0 0 0.5 0 1 0
P.G. 0 0 0 0 0 0
Z.G. 0 0 0 0 0 0
T.D. 0 0 nd nd nd nd
F.G. 0 0 1 0 0.5 0
A.B. 0 0 0.5 0 0 0
Mean 0.1 0 0.6 0 0.2 0
Range (0–0.5) (0–0) (0–1.5) (0–0) (0–1) (0–0)
No lesions
L.R. 0.5 0 nd nd nd nd
B.C. 0.5 0 1 0 nd 0
G.S. 0.5 0 0.5 1 1 0
M.M. 0 0 0.5 0 0.5 0
Mean 0.4 0 0.7 0.3 0.8 0
Range (0–0.5) (0–0) (0–1) (0–1) (0.5–1) (0–0)
Abbreviation: nd is not done.
a P , 0.05 vs. chronic graft rejection
sity of more than one (minimal) in two or more tubuli toxicity had a mild MCP-1 mRNA signal localized in the
were considered positive. As shown in Figure 2, in pa- tubular epithelial cells. Only one patient stained mini-
tients with CsA nephrotoxicity, 55% of biopsies stained mally for MCP-1 mRNA in the glomeruli (Table 4). At
positively for ET-1 mRNA at the tubular level, whereas variance, MCP-1 mRNA staining was almost negative
all of those from patients with chronic rejection or no in the tubuli of patients with chronic rejection at light
lesions at renal biopsy were negative. microscopy, being minimally stained in only one case.
As for RANTES mRNA in situ hybridization, an in- None of these patients had staining for MCP-1 mRNA
tense staining signal was found in tubuli of patients with at the glomerular level. Minimal tubular MCP-1 mRNA
CsA nephrotoxicity, whereas glomeruli stained mini- staining was also found in one patient with no renal
mally for this chemokine (Table 4 and Fig. 3). Strong lesions at light microscopy. As for the frequency of tubu-
RANTES mRNA expression was observed in interstitial lar staining, 70% of biopsies from patients with CsA
inflammatory cells (Fig. 3). Tubular staining of RANTES nephrotoxicity were positive for MCP-1 mRNA, and
mRNA was also observed in the biopsies from patients only 14% of those from patients with chronic rejection
with chronic rejection, but the intensity was lower. No (Fig. 2).
glomerular staining of RANTES was documented in
these patients. Minimal tubular and glomerular staining
DISCUSSIONwas found in some patients with no renal lesions at light
Here we have shown that 10 out of 22 kidney trans-microscopy. The frequency of positive RANTES mRNA
plant recipients who underwent protocol biopsy hadstaining at the tubular level was 60%, 42%, and 33% in
CsA-induced nephrotoxicity at histological examination.patients with CsA nephrotoxicity, chronic rejection, and
The morphological findings were supported by CsAno renal biopsy lesions, respectively (Fig. 2).
As shown in Figure 4, most patients with CsA nephro- pharmacokinetic parameters showing higher AUC and
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Fig. 1. Photomicrograph showing a representative distribution of endothelin-1 (ET-1) mRNA by in situ hybridization in kidney sections from a
patient with cyclosporine A (CsA) nephrotoxicity at renal biopsy. Intense staining was observed in tubular epithelial cells (a, magnification 390;
b, 3360; and c, 3180). Negative control using ET-1 sense probe in an adjacent kidney section is shown (d, 3180).
trough CsA blood levels in these patients than in those data in patients with autoimmune diseases, including
insulin-dependent diabetes of recent onset, uveitis, psori-with histologically diagnosed chronic rejection. Renal
function, however, was well preserved, as documented asis, Sjo¨gren’s syndrome, or polychondritis, given rela-
tively high doses of CsA [30]. In these categories ofby GFR values comparable to those of patients with
normal renal biopsy. Defining the role of CsA on long- patients, tubulointerstitial injury was the most common
feature at renal biopsy, and lesions were not related toterm renal structure and function changes after trans-
plantation is a difficult task. Chronic rejection, recurrent the number of glomeruli with global or segmental sclero-
sis nor to the degree of arteriolar injury. On the otherrenal disease, and other factors, including hypertension,
hyperlipidemia, and age, can lead to progressive renal hand, the glomerulosclerosis reported in heart transplant
recipients given CsA was most likely due to extensivestructural and functional deterioration [29]. No studies
have attempted to establish the role, if any, of CsA in tubulointerstitial and arteriolar injury [8, 13, 31] in pa-
tients who were exposed to very high doses of CsA soonisolation, and both structure and function were never
measured together in the same patients. Here, we com- after transplantation. Collectively, these findings tend to
suggest that unless one uses very high doses of CsA,bined structural, functional, and pharmacokinetic studies
to try to evaluate the impact of chronic CsA administra- tubulointerstitial injury appears independently from the
acute ischemic insults to afferent arterioles.tion on kidney transplant recipients.
In all patients with light microscopy evidence of CsA Our patients with biopsy evidence of CsA nephrotox-
icity probably had some degree of renal hypoperfusionnephrotoxicity, we found tubular atrophy and interstitial
fibrosis, whereas glomerular and arteriolar lesions were as reflected by a lower than normal mean RPF, which
was never found in patients with no lesions at renalless frequent. These findings are consistent with previous
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which mimics the human renal pathology of chronic CsA
nephropathy, interstitial fibrosis is mediated, at least
partly, through angiotensin II induction of transforming
growth factor-b1 (TGF-b1) expression [33]. Indeed, in
these rats, angiotensin-converting enzyme inhibition, as
well as angiotensin II receptor blockade, decreased the
expression of TGF-b1 and markedly reduced tubuloin-
terstitial fibrosis. However, the structural changes in this
model are probably related to salt depletion that turns on
angiotensin II-dependent growth factors for interstitial
fibroblasts, lymphokines, and cytokines, thus questioning
the role of angiotensin II in chronic CsA interstitial in-
jury in humans who are mostly on a normal-sodium diet.
In this study, we found an intense staining for ET-1,
RANTES, and MCP-1 mRNAs selectively localized at
tubular epithelial cells in biopsies taken from patients
with light microscopy evidence of chronic CsA nephro-
toxicity. This was never observed in patients with chronic
graft rejection whose tubuli did not stain for ET-1 and
MCP-1 mRNAs at all, with only minimal staining for
RANTES mRNA on a few occasions. It is tempting to
speculate that CsA exerts its renal toxicity on tubular
epithelial cells by inducing excessive formation of vaso-
active and chemotactic mediators that are then secreted
toward the basolateral compartment of tubular cells, thus
contributing to the inflammatory reaction and subse-
quent fibrosis of the interstitium. Data are available that
human interstitial fibroblasts challenged with ET-1 in-
crease their proliferation rate and actively synthesize
extracellular matrix proteins [34]. It also seems that there
is an amplification loop that further enhances the ET-1
synthetic rate [35] to the extent that fibronectin, collagen
type IV, and laminin added to culture media of tubular
cells stimulate ET-1 production. Beside ET, it is now
evident that a number of additional chemoattractants, in-
cluding RANTES and MCP-1, may act to amplify tubulo-
interstitial injury by recruiting mononuclear cells, which
are then activated to secrete TGF-b1 that induces fibro-
blasts to proliferate and secrete matrix components, con-
tributing to interstitial remodeling and scarring [36, 37].Fig. 2. Frequency of positive tubular staining for (A) endothelin-1
(ET-1), (B ) RANTES (regulated upon activation, normal T cell ex- Various reports proposed a link between CsA and ET.
pressed and secreted), and (C ) monocyte chemoattractant protein-1
Exposure of bovine aortic endothelial cells to CsA was(MCP-1) mRNAs in the kidney allograft biopsies from the three groups
associated with a concentration-dependent increase inof transplanted recipients. Staining was considered positive when the
score staining intensity was $1 in two or more tubuli. The numbers ET release in the incubation medium [38]. Similarly,
indicate positive staining/total biopsies analyzed.
Bunchman and Brookshire showed a direct effect of CsA
on ET release from cultured human endothelial cells
[39]. Evidence is also available that proximal tubular
cells in culture enhanced ET-1 synthesis when exposedbiopsy. One cannot exclude that vasoconstriction in the
absence of structural arteriolar lesions contributes to to CsA [40]. Moreover, in vivo in rats, CsA intake was
accompanied by an increase of urinary ET excretion [41].interstitial damage, but in animals given CsA, even at
high doses, hemodynamic changes are never associated On the other hand, no data are available on the ability
of CsA to stimulate RANTES and MCP-1 generationwith major structural interstitial injury [32].
How tubulointerstitial injury induced by CsA develops by tubular epithelial cells. Because it has been shown
that CsA accumulates in the tubular cells during chronicremains unknown. In an animal model of chronic CsA
nephrotoxicity produced by one week of salt depletion, administration [42, 43], one can hypothesize that high
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Fig. 3. Representative RANTES mRNA distribution by in situ hybridization in the kidney from a patient with CsA nephrotoxicity. Intense
staining was found in tubuli (a, magnification 3360), whereas weak staining in parietal epithelial cells of the glomerulus was observed (c, 3360).
Strong staining was observed in interstitial inflammatory cells (e, 3360). Negative control was obtained by hybridization with a sense probe (b,
d, f, 3360).
intracellular concentration of the drug may activate the stration that CsA is an inhibitor of the multidrug resis-
tance transporter, p-glycoprotein, which is constitutivelysynthetic machinery for ET-1 and possibly for the other
chemokines. This possibility is supported by the demon- expressed on the epithelial cells of renal tubuli [44].
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Fig. 4. Staining for MCP-1 mRNA by in situ hybridization in the kidney from a patient with CsA nephrotoxicity. Staining for MCP-1 mRNA
was mild either in tubuli (a, magnification 3180; b, magnification 3360) as well as in glomeruli (d, magnification 3360). No signal was detected
in the negative control hybridized with a sense probe (c and e, magnification 3360).
Inhibition of this transporter could allow the accumula- recently and consistently shown in in vitro studies in
cultured proximal tubular cells exposed to an excessivetion of CsA into tubular cells that theoretically would
result in enhanced generation of mediators of tubuloin- amount of proteins for a protracted period of time. In-
deed, increasing concentration of delipidated albumin,terstitial injury. This is reminiscent of what has been
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